Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 2290-2292, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Connor, J. F.
Right arrow Articles by Iles, R. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O’Connor, J. F.
Right arrow Articles by Iles, R. K.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:2290-2292.)
© 1999 American Association for Clinical Chemistry, Inc.

Letters

Interference of Luteinizing Hormone ß-Core Fragment in Urinary Gonadotropin Assays

John F. O’Connor1,2,a, Galina Kovalevskaya1 and Steven Birken3

1 Irving Center for Clinical Research, and Departments of
2 Pathology, and
3 Medicine, Columbia University College, of Physicians and Surgeons, New York, NY 10032
a Address correspondence to this author at: Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, 630 W. 168th St., PH10-305, New York, NY 10032. Fax 212-305-3213; e-mail jfo1@columbia.edu.


To the Editor:

Iles et al. (1) speculated on the value of development of a specific assay to measure human luteinizing hormone ß-core fragment (hLHßcf) without cross-reactivity with human chorionic gonadotropin ß-core fragment (hCGßcf). We wish to draw readers’ attention to the fact that we developed and reported such a specific assay for hLHßcf in 1995 (2) and reviewed the applications of this assay in 1996 (3). We wrote (3) that the assay "may have useful applications in tumor marker assays, pregnancy tests, and menopause". The hLHßcf assay (B505-B503) exhibits 1% cross-reactivity with hLH and 0.1% cross-reactivity with hCGßcf. We found that the assay detects the urinary form of hLHßcf in the urine of normally ovulating women (2). We applied this assay to the urine of postmenopausal women and found significant quantities of hLHßcf but not hCGßcf. The mean concentration of hLHßcf for 107 samples from postmenopausal women was 236 pmol/g creatinine (4). We also measured hCGßcf in the same samples and found that its concentration was one-tenth that of hLHßcf. For hCGßcf, we used our laboratory assay B210-B108 (5), which has 2% cross-reactivity with hLHßcf. These data suggest that to use hCGßcf as a cancer marker, an assay of very high specificity for this molecule is required because . . . [Full Text of this Article]


References

Ray K. Iles

Williamson Laboratory, St. Bartholomew’s and, The Royal London School, of Medicine and Dentistry, London EC1A 7BE, UK, E-mail R.K.Iles@mds.qmw.ac.uk
a Address correspondence to this author at: Irving Center for Clinical Research, Columbia University College of Physicians and Surgeons, 630 W. 168th St., PH10-305, New York, NY 10032. Fax 212-305-3213; e-mail jfo1@columbia.edu.


To the Editor:

The dynamics of LHßcf release into urine and its relation to LH metabolism.
Cross-reactivity effects of the urinary metabolites in studies of ectopic hCG expression.

Does LHßcf cross-react in ovulation prediction kits, and if so, does this give a false timing of ovulation?


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.